| Identification | Back Directory | [Name]
PHYLLANTHIN | [CAS]
10351-88-9 | [Synonyms]
NSC 619043
PHYLLANTHIN
Subfoliar Pearlin
Phyllanthin (15 mg)
PHOSPHO-L-SERINE, O-(RG)
3,3',4,4',9,9'-HexaMethoxylignan
Tetra-O-Methylsecoisolariciresinol
(2S,3S)-(+)-1,4-Dimethoxy-2,3-diveratrylbutane
1,1'-[(2S,3S)-2,3-Bis(methoxymethyl)-1,4-butanediyl]bis[3,4-dimethoxybenzene]
Benzene,1,1'-[(2S,3S)-2,3-bis(methoxymethyl)-1,4-butanediyl]bis[3,4-dimethoxy- | [Molecular Formula]
C14H17NO3 | [MDL Number]
MFCD03424460 | [MOL File]
10351-88-9.mol | [Molecular Weight]
247.29 |
| Chemical Properties | Back Directory | [Melting point ]
96℃ | [Boiling point ]
530.6±50.0 °C(Predicted) | [density ]
1.069 | [storage temp. ]
15-25°C | [solubility ]
DMF: 15 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml | [form ]
neat | [color ]
White to off-white | [BRN ]
2066503 | [LogP]
4.110 (est) |
| Hazard Information | Back Directory | [Uses]
Phyllanthin is a chemical extract from the Phyllanthus niruri plant and displays pharmacological effects as an anti-diabetic action, anti-arthritic, and inhibitor of P-gp. | [Definition]
ChEBI: Phyllanthin is a lignan. | [in vivo]
Phyllanthin (10 mg/kg; oral administration; once a day; 30 days) has protective effects in carbon tetrachloride (HY-Y0298) induced hepatotoxicity and experimental liver fibrosis in mice [2].
Phyllanthin (30 mg/kg; oral administration; single dose) exerts anti-tumor effects in diethylnitrosamine (HY-N7434) induced liver carcinogenesis in rats [5].
Phyllanthin (20-100 mg/kg; oral administration; once a day; 14 days) inhibits cellular and humoral immune responses in Balb/C mice [6]. | Animal Model: | Carbon tetrachloride (HY-Y0298) treated Swiss strain female mice (32-35 g) [2] | | Dosage: | 10 mg/kg | | Administration: | Oral administration (p.o.); once a day; 30 days | | Result: | Normalized the level of liver marker enzymes (ALT and AST) and collagen content in hepatotoxicity and experimental liver fibrosis mice.
Restored normal liver architecture, reversed the formation of continuous fibrotic septa between the central and portal veins and nodules.
Reduced the levels of TGF-β1, ALK5, p-Smad2 and p-Smad3 in hepatotoxicity and experimental liver fibrosis mice.
|
| Animal Model: | Diethylnitrosamine (Cat. No. HY-N7434) treated male Wistar albino rats (210-230 g)[5] | | Dosage: | 30 mg/kg | | Administration: | Oral administration (p.o.); single dose | | Result: | Significantly reduced 8-OHdG levels and delayed the oxidative damage in diethylnitrosamine -induced liver cancer rats.
Significantly reduced liver tissue injury biomarkers (ALT, AST, GGT, ALP and LDH) levels and tumor markers (AFP and CEA).
Reduced cellular enlargement, nodules, and hyperplasiaenlargement in diethylnitrosamine-induced liver tissue. |
| Animal Model: | Male Balb/C mice aged 6-8 weeks old (18-22 g) [6] | | Dosage: | 20 mg/kg, 40 mg/kg, and 100 mg/kg | | Administration: | Oral administration (p.o.); once a day; 14 days | | Result: | Dose-dependently inhibited CD11b/CD18 adhesion, the engulfment of E.coli by peritoneal macrophages molecules, NO and MPO release.
Dose-dependently inhibited T and B lymphocytes proliferation and down-regulated Th1 (IL-2 and IFN-γ) and Th2 (IL-4) cytokines.
Dose-dependently inhibited the sheep red blood cell (sRBC)-induced swelling rate of mice paw in delayed type hypersensitivity.
Significantly inhibited the serum levels of ceruloplasmin and lysozyme at higher doses (40 and 100 mg/kg).
Dose-dependently down-regulated anti-sRBC immunoglobulins (IgM and IgG) antibody titer. |
|
|
| Company Name: |
GK Chemicals
|
| Tel: |
+91-7207279444 +91-7207279444 |
| Website: |
www.www.info@gkchemicalss.com |
|